IRVINE, Calif., April 23, 2015 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today reported net income for the quarter ended March 31, 2015 of $123.4 million, or $1.12 per diluted share. Net income for the same period a year earlier was $60.3 million, or $0.56 per diluted share, and non-GAAP net income was $82.1 million, or $0.76 per diluted share.
Net sales for the quarter ended March 31, 2015 increased 13.0 percent to $590.3 million compared to the same period last year. Underlying1 sales grew 21 percent. U.S. and international segment sales for the first quarter were $283.5 million and $306.8 million, respectively.
“For the quarter, we experienced strong performance across all product lines and regions, again led by significant growth in transcatheter heart valves sales,” said Michael A. Mussallem, chairman and CEO. “Our newest innovative products helped us strengthen our global leadership positions and, most importantly, we believe even more patients with serious needs are benefiting from our technologies than ever before.”
Sales Results
For the first quarter, the company reported Transcatheter Heart Valve Therapy (THV) sales of $268.5 million, a 42 percent growth rate over the first quarter last year. On an underlying basis, THV sales grew 51 percent driven by continuing strong procedure growth in all major geographies and sales of new innovative products. Globally, average selling prices remained stable.
In the U.S., THV sales for the quarter, including royalties, were $130.8 million, representing growth of 84.0 percent over the year ago period. On an underlying basis, sales grew 67.3 percent. International THV sales were $137.7 million, representing 16.6 percent growth.
“Outside the U.S., THV sales grew 38 percent on an underlying basis during the quarter, once again driven by strong procedure growth in Europe and the ongoing launch in Japan,” said Mussallem. “While we expect this procedure growth rate to slow and competition to build, we continue to believe there are large numbers of untreated patients who can benefit from transcatheter aortic valve replacement therapy.”
Surgical Heart Valve Therapy product group sales for the quarter were $196.9 million. Sales decreased 2.8 percent over the first quarter last year, and increased 4.8 percent on an underlying basis.
“While our SAPIEN family of transcatheter valves grew rapidly, we continued to see solid unit growth of our surgical valve portfolio,” said Mussallem. A favorable product mix also contributed to a slightly higher overall average selling price.
Critical Care product group sales were $124.9 million for the quarter, representing a decrease of 4.4 percent versus last year, or an increase of 3.1 percent on an underlying basis. Usage of Enhanced Surgical Recovery products, including FloTrac and ClearSight, grew approximately 20 percent.
Additional Operating Results
For the quarter, the company’s gross profit margin was 77.0 percent, compared to 72.1 percent in the same period last year. This increase was driven primarily by a positive impact from foreign exchange. Last year’s THV product exchange and a more profitable product mix this year also contributed to the increase. At current rates, as the favorable hedge contracts expire, the company expects this rate to decline in 2016.
Selling, general and administrative expenses were $202.5 million for the quarter, or 34.3 percent of sales. The company expects SG&A, excluding special items, to be between 35 and 36 percent of sales for the full year.
Research and development investments for the quarter were $86.4 million compared to $85.8 million in the prior year period. Although Edwards continued to invest heavily in transcatheter valve programs, expenses were lower than anticipated as certain THV clinical expenses expected in the first quarter are now expected to occur in the second.
Cash flow from operating activities for the quarter was $73.3 million. After capital spending of $20.8 million, free cash flow was $52.5 million.
Cash, cash equivalents and short-term investments totaled $1.4 billion at March 31, 2015. Total debt was $602.7 million.
Outlook
The company now expects full year 2015 total sales to be within its original guidance of $2.3 billion to $2.5 billion. The company narrowed its guidance for full year 2015 diluted earnings per share, excluding special items, to a range of $4.10 to $4.30, from its previous range of $4.00 to $4.30. For the second quarter of 2015, at current foreign exchange rates, the company projects total sales to be between $580 million and $620 million, and diluted earnings per share, excluding special items, to be between $1.00 and $1.10.
“We are very pleased with the strong start to the year as we continue to focus on driving growth with leading innovative technologies,” said Mussallem. “Our foundation of leadership, coupled with a robust product pipeline, positions us well for continued longer-term success and greater shareholder value. We are confident in our outlook for continued strong sales growth and remain passionate about helping more patients around the world.”
About Edwards Lifesciences
Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring, enabling them to save and enhance lives. Additional company information can be found at www.edwards.com.
Conference Call and Webcast Information
Edwards Lifesciences will be hosting a conference call today at 2:00 p.m. PT to discuss its first quarter results. To participate in the conference call, dial (877) 407-8037 or (201) 689-8037. For 72 hours following the call, an audio replay can be accessed by dialing (877) 660-6853 or (201) 612-7415 and using conference number 13605453. The call will also be available via live or archived webcast on the “Investor Relations” section of the Edwards web site at ir.edwards.com or www.edwards.com. A live stream and archived replay can also be accessed via mobile devices by downloading Edwards’ IR App for iPhone and iPad or Android.
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements can sometimes be identified by the use of words such as “may,” “will,” “should,” “anticipate,” “believe,” “plan,” “project,” “estimate,” “expect,” “intend,” “guidance,” “outlook,” “optimistic,” “aspire,” “confident” or other forms of these words or similar expressions and include, but are not limited to, statements made by Mr. Mussallem, information in the Outlook section and the company’s financial guidance. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. If the company does update or correct one or more of these statements, investors and others should not conclude that the company will make additional updates or corrections.
Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements include uncertainties associated with the rate of adoption of TAVR therapy; timing and effectiveness of new product launches; competitive dynamics, particularly in the TAVR segment; the timing and extent of regulatory approvals and reimbursement levels for our products; the company’s success in developing new products, and avoiding manufacturing and quality issues; the impact of currency exchange rates and currency hedge contracts; the timing or results of pending or future clinical trials; actions by the U.S. Food and Drug Administration and other regulatory agencies; unexpected litigation results or expenses; and other risks detailed in the company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2014, which are available at edwards.com.
To read full press release, please click here.
Help employers find you! Check out all the jobs and post your resume.
